Neurocisticercose

Arq Neuropsiquiatr Arquivos de Neuro-Psiquiatria Arq. Neuro-Psiquiatr. 1678-4227 0004-282X Academia Brasileira de Neurologia - ABNEURO A cisticercose é uma das doenças parasitárias mais frequentes do sistema nervoso humano e constitui grave problema de saúde pública na maioria dos países em desenvolvimento. As manifestações clínicas da neurocisticercose (NCC) estão na dependência do número, tipo, localização e estágio de desenvolvimento dos cisticercos, assim como da resposta imunológica do hospedeiro contra o parasita. O diagnóstico da NCC é baseado nos exames de neuroimagem (tomografia computadorizada, ressonância magnética) e na detecção de antígenos/anticorpos no soro e no líquido cefalorraquiano. O tratamento antiparasitário tem sido marcado por uma intensa controvérsia. Os ensaios controlados e randomizados avaliando os benefícios clínicos da terapêutica têm revelado dados conflitantes em que alguns estudos indicam um benefício e outros não. As estratégias de prevenção devem ser fundamentadas na adoção simultânea de múltiplas medidas, adaptadas às características específicas de uma determinada região endêmica. Cysticercosis, an infection caused by the encysted larval stage of the tapeworm Taenia solium, is one of the most common parasitic diseases of the nervous system in humans, and constitutes a major public health problem for most of the developing world1. Clinical features The clinical manifestations of neurocysticercosis (NCC) largely depend on the number, type, size, localization, and stage of development of cysticerci, as well as on the host immune response against the parasite2-5. There are no pathognomonic features or a typical NCC syndrome. Whenever NCC is intraparenchymal it is usually associated with a good prognosis. Frequently, patients with few intraparenchymal cysts remain asymptomatic, although some patients develop seizures. On the other hand, in patients with massive cerebral infection, uncontrolled seizures and cognitive deficit may develop. Seizures are the most common manifestations of NCC (70–90%) of patients, followed by headache (38%), focal deficits (16%) and signs of intracranial hypertension (ICH) (12%). Other manifestations occur in less than 10% of symptomatic patients3. While many patients present with single or group of seizures at various stages of NCC, not all patients develop recurrent seizures or epilepsy6. A series including mostly patients with mild forms of infection showed that about 50% of patients with NCC presenting a seizure have further seizures7. When cysticerci lodge within the ventricular system a life-threatening acute intracranial hypertension secondary to hydrocephalus may develop. It is directly related to obstruction of the flow of CSF by the cyst or by inflammatory reaction of the ependyma. Although the cysts may be found anywhere within the ventricular system, the fourth ventricle is most commonly involved1 8. Cysts in the subarachnoid space may invade the Sylvian fissure and grow to large sizes, reaching several centimeters in diameter (giant cysts), causing intracranial hypertension with hemiparesis, partial seizures or other focal neurological signs. Subarachnoid cysts may also invade the basal cisterns; initially the growing membranes resemble a brunch of grapes, hence this form of disease is called “racemose” cysticercosis. It is associated with an intense inflammatory reaction, fibrosis and progressive thickening of the leptomeninges at the base of the brain9. In approximately 50-60% of the cases, there is an obstruction of the CSF circulation, resulting in hydrocephalus and progressive intracranial hypertension and mortality over 20% of cases8. When hydrocephalus secondary to cysticercotic meningitis is present, mortality is high (50%), and most patients die within 2 years after CSF shunting10. Therefore, ventricular and basal cisternal locations are considered to be malignant forms of neurocysticercosis11. Diagnosis The diagnosis of NCC is based upon neuroimaging studies and antibody/antigen detection in the serum and the cerebrospinal fluid (CSF). Neuroimaging is essential to the diagnosis of NCC. Early in the infection, a viable cyst appears as a spherical hypodense lesion on computerized tomography (CT) and as a CSF-like signal on magnetic resonance imaging (MRI). Both CT and MRI are able to show the invaginated scolex. In the degenerative phase, the cyst shows a ring-like or a nodular contrast enhancement, with or without perilesional edema. A final stage is observed when the cyst dies and a process of mineralization and resorption takes place, resulting in a calcified nodule. Since the cyst membrane is thin and the fluid is isodense within the CSF, noninflamed extraparenchymal (ventricular or subarachnoid) cysticerci are usually not visible on CT and may only reveal subtle, indirect findings on MRI scans. Analysis of CSF samples is an important parameter for the assessment and follow-up of patients with a suspicion of NCC. The most frequent CSF alterations are mononuclear pleocytosis and the presence of eosinophils and specific antibodies detected by enzyme-linked immunosorbent assay (ELISA) or enzyme-linked immunoelectrotransfer blot assay (EITB). Because clinical manifestations are pleomorphic, most neuroimaging findings are not pathognomonic, and several immunological tests show low levels of sensitivity and specificity, Del Brutto et al. have proposed a diagnostic criterion for NCC based on a consensus meeting on cysticercosis12. Treatment of NCC The treatment modalities available to patients with NCC include surgery, symptomatic therapy and antiparasitic drugs. The symptomatic therapy is probably more important in NCC than in any other infectious disease13. Most patients with NCC present seizures and the administration of standard doses of a single-first-line antiepileptic drug such as phenytoin or carbamazepine usually results in adequate seizure control. The optimum length of antiepileptic drug therapy has not yet been determined, but it has been suggested that it should be continued until serial neuroimaging studies show resolution of acute lesions7 14. Since inflammation is the conspicuous accompaniment in most forms of NCC, corticosteroids represent the primary form for attenuating the inflammatory reaction that may cause severe recurrent seizures, focal neurological symptoms and intracranial hypertension syndrome. Additionally, corticosteroids are fundamental for patients with cysticercal encephalitis, arachnoiditis and angiitis. Only scarce controlled data exist to determine when and what type of corticosteroids and the treatment regime to use. Symptomatic treatment includes also the placement of ventricular shunts for hydrocephalus associated with intracranial hypertension syndrome. Anticysticercal drugs Therapy for NCC, formerly restricted to palliative measures, has advanced with the advent of two drugs considered to be effective: praziquantel (PZQ) and albendazole (ALB)15-17. The goal of anticysticercal therapy is the simultaneous destruction of multiple cysts then controlling the resulting inflammatory reaction with steroids. This strategy of preventing prolongation of brain inflammation due to degeneration of multiple cysts at different times would allow better clinical evolution than the natural progression of NCC. Most comparative investigations have shown that ALB is more effective than PZQ in reducing the number of cysts and in inducing overall clinical improvement, with a lower frequency of adverse reactions. However, most of these trials have been uncontrolled, observational imaging studies and none of them were designed to evaluate seizure control. The meta-analyses of comparative trials suggested that ALB is more effective than PZQ regarding clinically important outcomes in patients with NCC17 19. Controversies over anticysticercal therapy Anticysticercal therapy has been marked by an intense controversy. The descriptions of spontaneous resolution of parenchymal cysticercosis with benign evolution, risks of complications and reports of no long-term benefits have reinforced the debate over the usefulness and safety of anticysticercal therapy20. Most available data describing the effectiveness of anticysticercal treatment are from uncontrolled studies with a significant selection bias. Many studies have documented that antiparasitic therapy results in death and resolution of viable cysts, but the clinical benefit of this treatment has been questioned21. Randomized controlled trials evaluating the clinical benefit of treatment have yield conflicting data with some studies indicating a benefit and others failing to show a difference22 23. A systematic review by the Cochrane Collaboration concluded that although evidence from trials of adults with viable cysts suggests ALB may reduce the number of lesions, no difference was detected for recurrence of seizures24. Control and preventive measures By the first part of 20th Century, Taenia solim infections had been almost eradicated in Europe. This process took place several decades and required many changes in economic, educational and sanitary standards, and improvement in the effectiveness of medical and veterinary services, especially meat inspection. These are not likely to be duplicated soon in many parts of the developing world. Therefore, the realistic aim of control is to reduce the incidence and prevalence of T. solium infections in humans and pigs to the level that human neurocysticercosis does not constitute a major public health and economic problem in a given endemic area25. Potential strategies for the control of Taenia solium infections have been up-dated recently25. Of the six proposed approaches, three (based on medical and veterinary interventions) have the potential to meet short-term control goals. These are: treatment of human carriers, treatment of cysticercotic pigs, and vaccination of pigs. The other three are are more appropriate as components of long-term programs or have a supportive value in short-term control projects: improved sanitation, changes in pig husbandry, and higher levels of general education. The prevention strategies must rely on multiple approaches, tailoring each to the special features of the particular endemic area26. In 1992, a pilot project was launched in Ribeirão Preto, São Paulo, Brazil. The project included a number of environmental sanitation measures, meat inspection, monitoring of vegetable crops and commercial concerns, and active surveillance of taeniasis among food handlers27-30. References 1 1. Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol 2011;7:584-594. Nash TE Garcia HH Diagnosis and treatment of neurocysticercosis Nat Rev Neurol 2011 7 584 594 2 2. Fleury A, Escobar A, Fragoso G, et al. Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors. Trans R Soc Trop Med Hyg 2010;104:243-250. Fleury A Escobar A Fragoso G Clinical heterogeneity of human neurocysticercosis results from complex interactions among parasite, host and environmental factors Trans R Soc Trop Med Hyg 2010 104 243 250 3 3. Carabin H, Ndimubanzi PC, Budke CM, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis 2011;5:e1152. Carabin H Ndimubanzi PC Budke CM Clinical manifestations associated with neurocysticercosis: a systematic review PLoS Negl Trop Dis 2011 5 e1152 4 4. Takayanagui OM, Odashima NS. Clinical aspects of neurocysticercosis. Parasitol Int 2006;55 Suppl:S111-S115. Takayanagui OM Odashima NS Clinical aspects of neurocysticercosis Parasitol Int 2006 55 Suppl S111 S115 5 5. Pal DK, Carpio A, Sander JW. Neurocysticercosis and epilepsy in developing countries. J Neurol Neurosurg Psychiatry 2000;68:137-143. Pal DK Carpio A Sander JW Neurocysticercosis and epilepsy in developing countries J Neurol Neurosurg Psychiatry 2000 68 137 143 6 6. Nash TE, Del Brutto OH, Butman JA, et al. Calcific neurocysticercosis and epileptogenesis. Neurology 2004;62:1934-1938. Nash TE Del Brutto OH Butman JA Calcific neurocysticercosis and epileptogenesis Neurology 2004 62 1934 1938 7 7. Carpio A, Hauser WA. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002;59:1730-1734. Carpio A Hauser WA Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis Neurology 2002 59 1730 1734 8 8. Pittella JE. Neurocysticercosis. Brain Pathol 1997;7:681-693. Pittella JE Neurocysticercosis Brain Pathol 1997 7 681 693 9 9. Fleury A, Carrillo-Mezo R, Flisser A, et al. Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease. Expert Rev Anti Infect Ther 2011;9:123-133. Fleury A Carrillo-Mezo R Flisser A Subarachnoid basal neurocysticercosis: a focus on the most severe form of the disease Expert Rev Anti Infect Ther 2011 9 123 133 10 10. Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases. J Neurosurg 1987;66:686-689. Sotelo J Marin C Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases J Neurosurg 1987 66 686 689 11 11. Estanol B, Corona T, Abad P. A prognostic classification of cerebral cysticercosis: therapeutic implications. J Neurol Neurosurg Psychiatry 1986;49:1131-1134. Estanol B Corona T Abad P A prognostic classification of cerebral cysticercosis: therapeutic implications J Neurol Neurosurg Psychiatry 1986 49 1131 1134 12 12. Del Brutto OH, Rajshekhar V, White Jr AC, et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001;57:177-183. Del Brutto OH Rajshekhar V White AC Jr Proposed diagnostic criteria for neurocysticercosis Neurology 2001 57 177 183 13 13. Nash TE, Singh G, White AC, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006;67:1120-1127. Nash TE Singh G White AC Treatment of neurocysticercosis: current status and future research needs Neurology 2006 67 1120 1127 14 14. Carpio A, Escobar A, Hauser WA. Cysticercosis and epilepsy: a critical review. Epilepsia 1998;39:1025-1040. Carpio A Escobar A Hauser WA Cysticercosis and epilepsy: a critical review Epilepsia 1998 39 1025 1040 15 15. Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-756. Garcia HH Evans CA Nash TE Current consensus guidelines for treatment of neurocysticercosis Clin Microbiol Rev 2002 15 747 756 16 16. Takayanagui OM. Therapy for neurocysticercosis. Expert Rev Neurother 2004;4:129-139. Takayanagui OM Therapy for neurocysticercosis Expert Rev Neurother 2004 4 129 139 17 17. Takayanagui OM, Odashima NS, Bonato PS et al. Medical management of neurocysticercosis. Expert Opin Pharmacother 2011;12:2845-2856. Takayanagui OM Odashima NS Bonato PS et al Medical management of neurocysticercosis Expert Opin Pharmacother 2011 12 2845 2856 18 18. Del Brutto OH, Roos KL, Coffey CS, et al. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006;145:43-51. Del Brutto OH Roos KL Coffey CS Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel Ann Intern Med 2006 145 43 51 19 19. Matthaiou DK, Panos G, Adamidi ES, et al. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2:e194. Matthaiou DK Panos G Adamidi ES Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials PLoS Negl Trop Dis 2008 2 e194 20 20. Fleury A, Gomez T, Alvarez I, et al. High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003;22:139-145. Fleury A Gomez T Alvarez I High prevalence of calcified silent neurocysticercosis in a rural village of Mexico Neuroepidemiology 2003 22 139 145 21 21. Carpio A, Santillan F, Leon P, et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995;155:1982-1988. Carpio A Santillan F Leon P Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 1995 155 1982 1988 22 22. Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008;79:1050-1055. Carpio A Kelvin EA Bagiella E Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial J Neurol Neurosurg Psychiatry 2008 79 1050 1055 23 23. Garcia HH, Pretell EJ, Gilman RH, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249-258. Garcia HH Pretell EJ Gilman RH A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis N Engl J Med 2004 350 249 258 24 24. Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev 2010:CD000215. Abba K Ramaratnam S Ranganathan LN Anthelmintics for people with neurocysticercosis Cochrane Database Syst Rev 2010 CD000215 25 25. Pawlowski ZS, Allan JC, Meinardi H. Control measures for taeniosis and cysticercosis. In: Murrell KD (Ed.) WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis. Paris: World Health Organization; 2005:73-99. Pawlowski ZS Allan JC Meinardi H Control measures for taeniosis and cysticercosis In: Murrell KD WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis Paris World Health Organizatio 2005 73 99 26 26. Kysvsgaard NC, Murrell KD. Prevention of taeniosis and cysticercosis. In: Murrell KD (Ed.) WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis. Paris: World Health Organization, 2005:57-72. Kysvsgaard NC Murrell KD Prevention of taeniosis and cysticercosis. In: Murrell KD (Ed.) WHO/FAO/OIE Guidelines for the surveillance, prevention and control of taeniosis/cysticercosis Paris World Health Organization 2005 57 72 27 27. Takayanagui OM, Febrônio LHP, Bergamini AMM, et al. Fiscalização de hortas produtoras de verduras no município de Ribeirão Preto, SP. Rev Soc Bras Med Trop 2000;33:169-174. Takayanagui OM Febrônio LHP Bergamini AMM Fiscalização de hortas produtoras de verduras no município de Ribeirão Preto, SP Rev Soc Bras Med Trop 2000 33 169 174 28 28. Takayanagui OM, Oliveira CD, Bergamini AMM, et al. Fiscalização de verduras comercializadas no município de Ribeirão Preto, SP. Rev Soc Bras Med Trop 2001;34:37-41. Takayanagui OM Oliveira CD Bergamini AMM Fiscalização de verduras comercializadas no município de Ribeirão Preto, SP Rev Soc Bras Med Trop 2001 34 37 41 29 29. Capuano DM, Okino MHT, Bettini MJCB, et al. Busca ativa de teníase e de outras enteroparasitoses em manipuladores de alimentos no município de Ribeirão Preto, SP, Brasil. Rev Inst Adolfo Lutz 2002;61:33-38. Capuano DM Okino MHT Bettini MJCB Busca ativa de teníase e de outras enteroparasitoses em manipuladores de alimentos no município de Ribeirão Preto, SP, Brasil Rev Inst Adolfo Lutz 2002 61 33 38 30 30. Capuano DM, Lazzarini MPT, Giacometti Jr E, Takayanagui OM. Enteroparasitoses em manipuladores de alimentos do município de Ribeirão Preto - SP, Brasil, 2000. Rev Bras Epidem 2008;11:687-695. Capuano DM Lazzarini MPT Giacometti Jr E Takayanagui OM Enteroparasitoses em manipuladores de alimentos do município de Ribeirão Preto - SP, Brasil, 2000 Rev Bras Epidem 2008 11 687 695